Immunoregulatory effects of interleukin-17 and Th17 cells in graft-versus-host disease.
10.7534/j.issn.1009-2137.2014.03.054
- Author:
Yi-Feng CAI
1
,
2
;
De-Pei WU
3
Author Information
1. Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China
2. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu Province, China.
3. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu Province, China. E-mail: wudepei@suda.edu.cn.
- Publication Type:Journal Article
- MeSH:
Animals;
Graft vs Host Disease;
immunology;
therapy;
Humans;
Immunomodulation;
Interleukin-17;
immunology;
Mice;
Th17 Cells;
immunology
- From:
Journal of Experimental Hematology
2014;22(3):861-864
- CountryChina
- Language:Chinese
-
Abstract:
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an intensive therapy to cure high-risk haematological malignant disorders, congenital diseases, autoimmune disease and so on. The main complication of HSCT is graft-versus-host disease (GVHD), which can cause the death of recipients and affect the therapeutic effect. Many kinds of immune cells and inflammatory factors were involved in the occurrence of GVHD. Twenty years ago the mice and human interleukin-17 (IL-17) were found. A new kind of T cell-CD4(+) IL-17(+) T was found in recent years, named Th17 cells. Now IL-17 and Th17 cells have become the hot spot in the research field of infection immunity, autoimmune diseases, tumor immunity and GVHD. In this article, immunoregulatory effects of interleukin-17 and Th17 cells in GVHD are reviewed.
